1. Esketamine improves cognitive function in sepsis-associated encephalopathy by inhibiting microglia-mediated neuroinflammation.
- Author
-
Li H, Hu W, Wu Z, Tian B, Ren Y, and Zou X
- Subjects
- Animals, Mice, Male, Mice, Inbred C57BL, Cognitive Dysfunction drug therapy, Cognitive Dysfunction etiology, Indole Alkaloids pharmacology, Indole Alkaloids therapeutic use, Disease Models, Animal, Receptors, N-Methyl-D-Aspartate antagonists & inhibitors, Receptors, N-Methyl-D-Aspartate metabolism, Neuroprotective Agents pharmacology, Neuroprotective Agents therapeutic use, Neurons drug effects, Neurons pathology, Carbazoles, Ketamine pharmacology, Ketamine therapeutic use, Sepsis-Associated Encephalopathy drug therapy, Microglia drug effects, Microglia metabolism, Microglia pathology, Cognition drug effects, Brain-Derived Neurotrophic Factor metabolism, Neuroinflammatory Diseases drug therapy
- Abstract
Microglia-mediated neuroinflammation is critical in the pathogenesis of sepsis-associated encephalopathy(SAE). Identifying the key factors that inhibit microglia-mediated neuroinflammation holds promise as a potential target for preventing and treating SAE. Esketamine, a non-competitive N-methyl-D-aspartate (NMDA) receptor antagonist, has been proposed to possess protective and therapeutic properties against neuroinflammatory disorders. This study provides evidence that the administration of Esketamine in SAE mice improves cognitive impairments and alleviates neuronal damage by inhibiting the microglia-mediated neuroinflammation. The BDNF receptor antagonist K252a was employed in both vivo and in vitro experiments. The findings indicate that K252a successfully counteracted the beneficial effects of Esketamine on microglia and cognitive behavior in mice with SAE. Consequently, these results suggest that Esketamine inhibits microglia-mediated neuroinflammation by activating the BDNF pathway, and mitigating neuronal damage and cognitive dysfunction associated with SAE., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024. Published by Elsevier B.V.)
- Published
- 2024
- Full Text
- View/download PDF